By Brian Kohr, CSafe Global, President and CEO
Manufacturers and shippers of these products are under increasing pressure, as pharmaceutical and life science logistics becomes more complex and as the consideration towards better control of falsified medicines increases.
For most pharmaceutical companies (and perhaps those particularly operating under the regulatory guidance of the EU), a key challenge is the ability to create and maintain an innovative and competitive distribution channel strategy. This means looking beyond the traditional cost components of ‘transportation’ and taking a wider view of all the elements that go to make up the total cost of distribution. All of this is of course against a regulatory background that has placed much more GDP compliance in the hands of pharmaceutical manufacturers of finished products or API.